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Abstract
Dentine matrix has proposed roles for directing mineralised tissue repair in dentine and bone; however, 
the range of bioactive components in dentine and specific biological effects on bone-derived mesenchymal 
stem cells (MSCs) in humans are less well understood. The aims of this study were to further elucidate the 
biological response of MSCs to demineralised dentine matrix (DDM) in enhancing wound repair responses 
and ascertain key contributing components. Dentine was obtained from human teeth and DDM proteins 
solubilised with ethylenediaminetetraacetic acid (EDTA). Bone marrow derived MSCs were commercially 
obtained. Cells with a more immature phenotype were then selected by preferential fibronectin adhesion 
(FN-BMMSCs) for use in subsequent in vitro assays. DDM at 10 µg/mL reduced cell expansion, attenuated 
apoptosis and was the minimal concentration capable of inducing osteoblastic differentiation. Enzyme-linked 
immunosorbent assay (ELISA) quantification of growth factors indicated physiological levels produced the 
above responses; transforming growth factor β (TGF-β1) was predominant (15.6 ng/mg DDM), with relatively 
lower concentrations of BMP-2, FGF, VEGF and PDGF (6.2-4.7 ng/mg DDM). Fractionation of growth factors 
from other DDM components by heparin affinity chromatography diminished osteogenic responses. Depletion 
of biglycan from DDM also attenuated osteogenic potency, which was partially rescued by the isolated 
biglycan. Decorin depletion from DDM had no influence on osteogenic potency. Collectively, these results 
demonstrate the potential of DDM for the delivery of physiological levels of growth factors for bone repair 
processes, and substantiate a role for biglycan as an additional adjuvant for driving osteogenic pathways.
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Introduction
A plethora of growth factors, such as various isoforms 
of transforming growth factor β (TGF-β), bone 
morphogenetic proteins (BMPs), vascular endothelial 
growth factor (VEGF), fibroblast growth factors (FGF), 
platelet-derived growth factor (PDGF) and insulin-
like growth factor (IGF) are widely implicated in 
directing the early events of osteogenesis (Dimitriou 
et al., 2005). These growth factors have all been 
identified to play crucial roles in promoting cell 
migration to the repair site, proliferation and 
differentiation of endogenous MSCs to form bone 
synthesising osteoblasts (Roberts and Rosenbaum, 
2012),  in addition to promoting angiogenesis 
(Geiger et al., 2005). Indeed, it is against background 
research of growth factor roles as isolated entities 
that BMP-2 and BMP-7, have both been approved 
for therapeutic use in clinical practice (Axelrad and 
Einhorn, 2009). However, problems exist related to 
toxicity of the supraphysiological doses required to 
evoke a stimulatory response. Resultantly, the true 
efficacy of clinical success is questioned due to the 
potential for stimulating ectopic bone formation 
and inflammation (Zara et al., 2011; Lee et al., 2011). 
These issues have partially been addressed through 
administering combinations of growth factors where 
lower dosage levels have demonstrated enhanced 
osteogenic bioactivity in vitro and in vivo compared 
to individual factors (Kanczler et al., 2010; Tachi et al., 
2011; Simmons et al., 2004); strengthening evidence 
for the activities of multiple growth factors acting 
synergistically to deliver optimised signalling (Chen 
et al., 2010).
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 Dentine is recognised to possess the capacity to 
undergo endogenous regeneration in response to 
carious injury, where demineralisation results in 
the dissolution of bioactive constituents within the 
matrix. These released bioactive factors stimulate 
resident dental pulp-derived stem cells (DPSCs) 
to differentiate into odontoblast-like cells, which 
secrete a reparative mineralised matrix that is 
comparable in structure to bone (Smith et al., 
1995; Arana-Chavez and Massa, 2004). Due to the 
bioactive potential of dentine in vivo being limited 
to stimulating reparative responses within teeth, 
more recent studies have investigated the potential 
of demineralised dentine matrix (DDM) to stimulate 
bone repair. Placement of dentine in vivo has been 
reported to stimulate reparative bone formation in 
rabbit critical defects (Gomes et al., 2008) and in rat 
tooth sockets (de Oliveira et al., 2013). In vitro, DDM 
has been demonstrated to induce mineralisation 
and increased expression of bone forming markers 
of human DPSCs (Lee et al., 2015; Gonçalves et al., 
2016; Liu et al., 2016) and murine bone marrow MSCs 
(BMMSCs) (Yu et al., 2014). Proteomic studies of 
human dentine have identified the presence of up 
to 289 different components, with TGF-β1 identified 
as a prominent growth factor (Jágr et al., 2012; Chun 
et al., 2011; Park et al., 2009). Immuno-histochemical 
studies have also identified the additional presence 
of BMP-2 (Casagrande et al., 2010), vascular 
epidermal growth factor (VEGF) (Roberts-Clark 
and Smith, 2000) and IGF (Finkelman et al., 1990). 
Whilst the synergistic signalling activities of these 
growth factors are acknowledged in contributing to 
osteoblast differentiation and directing bone repair, 
there is an increasing recognition for contributions 
by other matrix constituents which are proposed 
to act to tether growth factors to the extracellular 
matrix and influence signalling activity. Members 
of the small leucine-rich proteoglycans (SLRPs), 
biglycan and decorin, are major constituents in 
dentine (Waddington et al., 2003a). These SLRPs 
have proposed roles in modulation of growth 
factor bioactivity and facilitating their sequestration 
within biological matrices, thereby protecting them 
from proteolysis, extending their extracellular 
half-life and regulating release to the cell (Baker et 
al., 2009). In addition, biglycan has been described 
to directly stimulate bone formation via dual 
signalling mechanisms of the BMP/TGFβ and the 
canonical Wnt/β-catenin pathways and hence has 
been proposed as a promising therapeutic in bone 
related diseases involving defects in these pathways 
(Nikitovic et al., 2012; Nastase et al., 2012).
 Both in vitro and in vivo studies have demonstrated 
an ability for dentine matrix components to drive 
mineralised tissue repair, and thus DDM may be 
regarded as a physiologically optimised bioactive 
matrix that is able to drive wound repair responses, 
and thus may have a therapeutic application for 
stimulating bone repair and regeneration. However, 
whilst the presence of prime growth factors with 
proposed roles in bone repair can presumed to 
be present, a fuller characterisation of the growth 
factor profile DDM contains still remains unknown. 
Further, the importance of other extracellular matrix 
components, such as the SLRPs, for synergistically 
enhancing growth factor activity has not previously 
been established as a key contributor to DDM’s 
bioactivity. Using human derived tissue and cells, 
this study quantified the physiological growth 
factor levels in DDM able to evoke an osteogenic 
response, in addition to confirming the presence of 
biglycan and decorin. Bioactivity of DDM, including 
determining dose effects, was examined, in order 
to dissect its regulatory activity on key biological 
events that are prerequisite for successful bone 
repair; namely, MSC migration, promoting cell 
survival and regulating proliferation, osteoblast 
differentiation and deposition of a mineralised 
matrix. Through fractionation of growth factors and 
immuno-depletion of decorin and biglycan matrix 
components, the importance of these components 
for driving osteogenesis of human BMMSCs was 
evaluated.
Materials and Methods
Preparation of demineralised dentine matrix (DDM)
Human teeth (representing healthy tissue from 
10 molars, pre-molars, canines and incisors) were 
obtained from Cardiff University School of Dentistry 
“Toothbank,” with patient informed consent in 
accordance with ethical approval granted by South 
East Wales Research Ethics Committee, (12/WA/0289). 
Enamel, cementum and soft tissues of the pulp 
and attached gingiva were dissected away and the 
remaining dentine (7.5 g) was powdered using a 
percussion mill cooled in liquid nitrogen. DDM was 
extracted from dentine powder using 7.5 % EDTA 
diNa+, as previously described by Lee et al. (2015). 
Soluble extracts were recovered by centrifugation 
at 1,100×g for 10 min, dialysed against double 
distilled water (ddwater) at 4 °C, lyophilised and 
stored at −20 °C (total of 0.5 g DDM produced for all 
subsequent experiments described). DDM aliquots 
were reconstituted to 1 mg/mL in tris-buffered saline 
(TBS) and sterile filtered through a 0.22 µM filter. 
Protein concentration was determined using a Pierce® BCA 
Assay Kit (Thermo Fisher Scientific, Newport, UK).
Characterisation of DDM
SDS-PAGE and Western blot analysis
DDM samples were separated by electrophoresis 
using 4-15 % Mini-PROTEAN® TGX pre-cast gels 
(Bio-Rad, Hemel Hempstead, Herts, UK) with 
running buffer 25 mM Tris, 192 mM glycine, 0.1 % 
SDS, pH 8.3, at 200 V. A Silver Stain Plus™ kit (Bio-
Rad, Hemel Hempstead, Herts, UK) was used to 
visualise protein. Western blot analysis of separated 
protein components were conducted as described 
by Sadaghiani et al. (2016). Details of antibodies 
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and blocking peptides are described in Table 1. 
Negative controls were performed by incubating 
primary antibodies with 10× excess of respective 
blocking peptide for 1 h prior to incubation with the 
membrane.
ELISA
DDM was reconstituted in α-MEM (containing 
ribonucleosides and deoxyribinucleosides) (Thermo 
Fisher Scientific, Newport, UK) and growth factors 
quantified using the following commercially 
available kits; Human TGF-β1 Platinum ELISA kit 
(eBioscience, Altrincham, Ches., UK); Human IGF-1 
Quantikine® ELISA kit (R&D Systems, Abingdon, 
Oxon, UK); Human BMP-4 and Human BMP-7 
ELISA kits respectively (Sigma-Aldrich, Poole, UK); 
BMP-2, VEGF, PDGF-BB and FGF-2 using respective 
Human Mini ELISA kits (PeproTech, London, UK). 
Assays were performed in triplicate on three separate 
occasions (two separate occasions for BMP-4 and 
BMP-7 where lack of material prevented analysis for 
detection of low growth factor levels).
Fractionation of DDM
Heparin affinity chromatography
DDM was reconstituted in binding buffer (0.01 M 
Tris-HCl / 0.1 M NaCl, pH 7, in 18.2 MΩ water) and 
passed through a sterile 0.22 µM syringe filter. Protein 
concentration was determined. 1.8 mg was applied 
to a Heparin HiTrap column, incorporated into an 
AKTA Purifier FPLC system (both GE Healthcare 
Life Sciences, Amersham, Bucks, UK) over 15 mL at 
1 mL/min. Flow through eluent (FT) was collected as 
one fraction. Bound DDM components were eluted 
by application of a linear 0.1-3 M NaCl gradient, over 
12 column volumes at 2 mL/min. 2.5 mL fractions 
were collected and subsequently pooled into EL1 and 
EL2, based on the 280 nm absorbance profile. Pooled 
fractions were dialysed against ddwater, lyophilised 
and re-suspended in TBS. Protein concentration in 
each fraction was determined and expressed as a 
percentage of original protein added to the column. 
TGFβ-1 and BMP-2 concentrations in each fraction 
were determined by ELISA and the presence of 
biglycan and decorin by Western blot analysis.
Immuno-precipitation of decorin and biglycan from DDM
Immunoprecipitation was achieved using a Pierce® 
Crosslink IP Kit (Thermo Fisher Scientific, Newport, 
UK), according to manufacturer’s protocol. Columns 
were cross-linked with either 10 μg biglycan (sc-27936) 
or decorin (sc-22613) antibody (both from Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA). 700 µg DDM 
was applied to respective antibody-loaded columns and 
incubated overnight. Biglycan / decorin depleted 
DDM, followed by bound material, was eluted from 
the column following manufacturer’s protocol. 
Eluents were dialysed against ddwater, lyophilised 
and re-suspended in TBS. Protein concentration was 
determined and expressed as a percentage of DDM 
applied to the column.
Cell source, preparation and culture
BMMSCs were obtained commercially (Lonza, 
Slough, UK; from a 30-year-old male donor). Cells 
were seeded at 5,000 cells/cm2 and cultured in basal 
medium (α-MEM containing ribonucleosides and 
deoxyribinucleosides (Thermo Fisher Scientific, 
Newport, UK), 10 % foetal calf serum (Invitrogen, 
Thermo Fisher Scientific, Newport, UK), 100 µM 
L-ascorbic-2-phosphate (Sigma-Aldrich, Poole, UK), 
1× Antibiotic/Antimycotic (Sigma-Aldrich, Poole, 
UK)), 37 °C, 5 % CO2. At 70-80 % confluence, a single 
cell suspension was produced using Accutase (PAA 
Laboratories GmbH, Pasching, Austria) and immature 
cells were selected by preferential adherence to 
fibronectin (human plasma; Sigma-Aldrich, Poole, 
UK) over 20 min, as described previously by Lee et al. 
(2015). Preferential selection of fibronectin-adherent 
BMMSCs was performed to increase the homogeneity 
of the cell population and reduce the effects of donor 
variability when replicating these experiments. 
Fibronectin adherent cells (FN-BMMSCs) and 
BMMSCs were culture expanded in the above media.
MSC characterisation
Population doublings (PDs)
At each passage, cell counts were determined and 
PDs calculated, proportional to cell numbers initially 
seeded:
Cells were reseeded at 4,000 cells/cm2.
Reverse Transcription PCR
BMMSCs and FN-BMMSCs were cultured until 
90-100 % confluent. RNA was extracted using an 
Primary antibody 
(Ab)
Primary Ab 
Dilution Secondary Ab
Secondary Ab 
dilution Blocking peptide
TGF-β1 (V) 1:200 Anti-rabbit HRP (sc-2030) – 1:25,000 TGF-β1 (V) 
BMP-2 (N-14) 1:500 Anti-goat HRP (sc-2020) 1:50,000 BMP-2 (N-14) 
VEFG (A-20) 1:200 Anti-rabbit HRP (sc-2030) 1:25,000 VEFG (A-20) 
Biglycan (L-15) 1:500 Anti-goat HRP (sc-2020) 1:50,000 N/A
Decorin (N-15) 1:300 Anti-goat HRP (sc-2020) 1:50,000 N/A
Table 1. Details of primary antibodies, corresponding secondary antibodies and respective 
blocking peptides (used to confirm specificity of antibody binding) for immuno detection in 
Western blot analysis and immuno-precipitation protocols. (All antibodies and blocking peptides 
from Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA; N/A not available).
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RNeasy kit (Qiagen, Hilden, Germany). cDNA was 
synthesised from 1 µg of total RNA using the M-MLV 
reverse transcriptase system (Promega, Southampton, 
UK,), amplified within a Thermal Cycler at 70 °C for 
5 min. Total human RNA (Clontech, Saint-Germain-en-
Laye, France) or nuclease free water to replace sample 
RNA served as respective positive or negative controls. 
Expression of purported mesenchymal, embryonic 
and haematopoietic stem cell markers was examined 
using a standard RT-PCR protocol with forward and 
reverse primers, detailed in Table 2, and the following 
cycling conditions: 1 initial denaturation at 95 °C, 
4 min; 35 cycles of 95 °C, 1 min and 72 °C, 1 min; 1 
final extension at 72 °C, 10 min. RT-PCR products 
were separated on 2 % agarose/ethidium bromide gels 
and visualised by UV light.
β-galactosidase staining
MSCs, cultured to suspected senescence as indicated 
by PD < 0.5, and pre-senescent cells were analysed. 
β-galactosidase staining was performed using a 
Senescent Cells Histochemical Staining Kit (Sigma-
Aldrich, Poole, UK).
Culture of FN-BMMSCs in the presence of DDM 
and fractions
For fractionated DDM samples, protein concentration 
added to culture media was adjusted to represent 
the percentage of total DDM as calculated above (i.e. 
percentage of 10 µg/mL).
MTT Cell expansion assay
FN-BMSCs (10 PDs) were seeded into 96-well plates 
at 4,000 cells/cm2 in 5 % foetal bovine serum (FBS) 
culture medium, supplemented with 0-10 µg/mL 
DDM or relative proportion of fractionated sample. 
Cell expansion was determined using a MTT assay 
(Sigma-Aldrich, Poole, UK) over a 0-96 h culture 
period.
Caspase apoptosis assay
FN-BMSCs (14.5 PD) were seeded into white-walled, 
optically clear 96-well plates at 4,000 cells/cm2 in 10 % 
FBS culture medium supplemented with 0-10 µg/mL 
DDM. Apoptotic cells were detected over 48 h using 
a Caspase-Glo® 3/7 Assay (Promega, Madison, WI, 
USA).
Cellular migration assay
Cell migration through collagen was measured 
using Boyden chamber assay system. 52.54 µL type 
1 collagen (supplied 3.7 mg/mL in 0.02 N acetic 
acid; Sigma-Aldrich, Poole, UK) was added to 1 mL 
α-MEM and neutralised with 10.58 µL 0.1 N NaOH. 
The uppermost surface of 24-well tissue culture 
inserts (8 µM pores; Greiner Bio-One, Stonehouse, 
Gene 
product Primer sequence: 5’-3’
Annealing 
temperature 
(°C)
Product 
length 
(bp) Application
GAPDH F: TTCTTTTGCGTCGCCAGCCGA
R: GTGACCAGGCGCCCAATACGA
55 96 RT PCR / qPCR
Housekeeping gene
CD105 F: GAAACAGTCCATTGTGACCTTCAG
R: GATGGCAGCTCTGTGGTGTTGACC
55 344 RT PCR
MSC marker
CD90 F: ATGAACCTGGCCATCAGCATCG
R: CACGAGGTGTTCTGAGCCAGCA
55 425 RT PCR
MSC marker
CD73 F: GTCGCGAACTTGCGCCTGGCCGCCAAG
R: TGCAGCGGCTGGCGTTGACGCACTTGC
55 352 RT PCR
MSC marker
CD146 F: TGTGTAGGGAGGAACGGGTA
R: TGGGACGACTGAATGTGGAC
55 101 RT PCR
MSC marker
CD34 F: GCTTTGCTTGCTGAGTTTGC
R: CCATGTTGAGACACAGGGTGC
55 180 RT PCR
Haemopoietic stem cell marker
CD45 F: CCCCACTGATGCCTACCTTA
R: ATGCACCTCATTGTTTGTGC
55 238 RT PCR
Haemopoietic stem cell marker
Oct4 F: GGTGGAGAGCAACTCCGAT
R: ATGGTCGTTTGGCTGAATACC
55 246 RT PCR
Embryonic MSC marker
Nanog F: AGGTCCCGGTCAAGAAACAG
R: CCCTGCGTCACACCATTG
55 235 RT PCR
Embryonic MSC marker
RunX2 F: GGTTAATCTCCGCAGGTCACT
R: CCCTCTGTTGTAAATACTGCTTGC
55 80 qPCR / RT PCR
Early osteoblast differentiation marker
CO-
L1A1
F: TGCTGTTGGTGCTAAGGG
R: GCAATACCAGGAGCACCATTG
55 177 qPCR 
Matrix deposition marker
OC F: GGCAGCGAGGTAGTGAAGAG
R: CTCACACACCTCCCTCCT
55 102 qPCR 
Late osteoblast differentiation marker
Table 2. Details of forward and reverse primer sequences and cycling conditions used for RT-PCR and qPCR. 
GAPDH was used as reference gene.
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Glos., UK) were coated with 10 µg of type I collagen 
in solution, left to solidify at 37 °C overnight and then 
air dried for 1 h at room temperature. FN-BMMSCs 
(12.6 PDs) were serum starved for 24 h and re-seeded 
at 10,000 cells/cm2 in 200 µL/well in serum-free culture 
medium onto the collagen-coated inserts. Inserts were 
placed into the lower chamber containing 600 µL/well 
serum-free medium supplemented with 0-10 µg/mL 
DDM and incubated at 37 °C, 5 % CO2. After 20 h 
medium in the lower compartment was replaced 
with 450 µL of serum-free culture medium containing 
8 µM Calcein-AM (Sigma-Aldrich, Poole, UK) and 
incubated at 37 °C for 45 min. This culture medium 
was then replaced with 500 µL of 0.05 % Trypsin-
EDTA (Sigma-Aldrich, Poole, UK) to detach cells over 
10 min at 37 °C. 200 µL of Trypsin solution was removed 
from each well and fluorescence read using 485 nm 
excitation/520 nm emission wavelengths.
Osteogenic differentiation
FN- BMMSCs (15-17 PD) were seeded at 10,000 
cells/cm2 and cultured in α-MEM basal medium 
supplemented with 0-10 µg/mL DDM or equivalent 
fractionated sample at 37 °C, 5 % CO2. Basal medium 
supplemented with 10 mM β-glycerophosphate and 
10 nM dexamethasone (both Sigma-Aldrich, Poole, 
UK) provided a positive osteogenic control.
Alizarin Red Staining
After 28 d, cultured cells were washed twice with 
PBS, fixed in 10 % formaldehyde (Sigma-Aldrich, 
Poole, UK), 30 min, washed twice in PBS and stained 
with 2 % (w/v) Alizarin Red S (pH 4.1-4.3) (Sigma-
Aldrich, Poole, UK) for 20 min. Cells were washed 
with ddwater and digital images captured with a 
light microscope.
Quantitative real-time PCR
Gene expression for osteogenic related markers 
RunX2, osteocalcin (OC) and Col1A1 was assessed. 
RNA was extracted from cultured cells and converted 
to cDNA by reverse transcription as described above. 
For qPCR analysis, cDNA was added to primer sets 
(Table 2) and PrecisionFAST Master Mix pre-mixed 
Fig. 1. Assessment of growth factor composition present in DDM. (A) Separation of DDM by SDS PAGE 
with strong silver staining protein bands evident at 80, 70 and 50 kDa. (B) Immuno-detection of TGF-β1, 
BMP-2 and VEGF within DDM, with all detected within the 50 kDa protein band. (C) Quantification of 
growth factors present in DDM using respective ELISA assays. From standard curves, growth factors were 
calculated to be present within the DDM in low ng to pg/mL concentration range, with TGF-β1 the most 
abundant growth factor. ELISAs were performed in triplicate on three separate occasions *= p < 0.05, ** = 
p < 0.01, *** = p < 0.001.
A B
C
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with SYBR green (Primer Design Ltd, Eastleigh, Hamps, 
UK). qPCR was performed using QuantStudio™ 6 Flex 
Real-Time PCR System (Thermo Fisher Scientific, 
Newport, UK) with the following cycling reaction 
conditions: 1 initial denaturation at 95 °C for 20 s; 
40 cycles of denaturation for 1 s, annealing for 20 s. 
GAPDH was the internal reference gene.
Statistical analysis
For all assays performed above, triplicate samples 
were analysed for each sample group examined, and 
assays were repeated on three separate occasions. 
Statistical analyses to determine analysis of variance 
between sample groups were performed by One-
Way ANOVA with a post-hoc Tukey test using Instat 
GraphPad software (GraphPad, La Jolla, CA, USA).
Results
Quantification of growths factors in DDM
Separation of DDM by SDS PAGE indicated the 
presence of protein material from 250 kDa to 
6 kDa, with strong bands at approximately 80 kDa, 
70 kDa and 50 kDa (Fig. 1A). Subsequent Western 
blot analysis of separated gels, indicated immuno-
positivity for TFG-β1, BMP-2 and VEGF at 50 kDa. 
Pre-incubation of the primary antibody with their 
respective blocking peptide confirmed specificity for 
the antibody used (Fig. 1B). ELISA quantification of 
growth factors revealed TGF-β1 as the most abundant 
growth factor (15.6 ± 7.9 ng/mg DDM; n = 3). FGF-
2, BMP-2, PDGF, VEGF and IGF-1 demonstrated 
intermediate abundance (6.2-2.4 ng/mg; n = 3). 
BMP-4 and BMP-7 represented the lowest abundant 
factors (approximately 120-72 pg/mg DDM; n = 2 as 
insufficient material available to accurately detect 
growth factors present at pg levels).
Isolation of immature FN-BMMSC cells from 
BMMSCs
Cells used in this study were selected for adherence 
to fibronectin to isolate the more immature MSC 
population (FN-BMMSCs; Lee et al., 2015; Jones 
and Watt, 1993), to reduce heterogeneity of the cell 
population and increase potential for reproducibility 
on these commercially derived cells, which would 
likely be obtained from different donors. Both 
BMMSCs and selected FN-BMMSCs expressed 
purported MSC markers (Reviewed by Mafi et al., 
Fig. 2. Comparison of MSC characteristics of commercial BMMSCs and the same cells selected by preferential 
fibronectin adherence to select a more immature cell population, FN-BMMSC. (A) Following culture 
expansion FN-BMMSCs demonstrated an ability to proliferate to approximately 20 PD whilst proliferation 
of parent BMMSCs started to slow at approximately 13 PDs. (B) RT-PCR demonstrated the expression of 
all classical MSC markers by both populations; an increase in the embryonic marker Nanog was observed 
for FN-BMMSC. (C) Culture expansion induced senescence within both cell populations as determined 
by blue cells staining for β-galactosidase; senescence developed at a later PD for FN-BMMSC cells. White 
scale bars represent 100 μM.
A B
C
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2011) CD105, CD90, CD73 and CD146, embryonic 
marker Oct4 and were negligible for haemopoietic 
markers CD34, CD45 (Fig 1B). The selection of 
more immature cells was indicated by an increased 
proliferative lifespan for FN-BMMSCs, which 
achieved >17 PDs in long-term culture (Fig. 2A), 
with 75 % of cells observed as senescent at 20.4 PDs 
(Fig. 2C); by comparison proliferation of BMMSCs 
slowed to <0.5 PD at 12 PD and demonstrated 
58.7 % senescent cells at 15.1 PD. In addition, FN-
BMMSCs expressed the embryonic stem cell marker 
Nanog (Mafi et al., 2011), which was perceived as 
less pronounced in BMMSCs (Fig. 2B), indicating 
that cells expressing an immature MSC phenotype 
remained following fibronectin selection.
Influence of DDM on FN-BMMSC cell behaviour
FN-BMMSCs supplemented with 10 µg/mL DDM 
significantly reduced cell expansion, apoptosis, 
cell migration (Fig. 3A-C) and was the minimal 
concentration able to induce formation of mineralising 
nodules (Fig. 3D), confirmed by increased gene 
expression of osteogenic markers RunX2, Col 1A1 
and OC (Fig. 3E). Lower concentrations of 0.1 and 
1 µg/mL DDM failed to produce an osteogenic 
response, reduced cell expansion to a lesser extent, 
albeit statistically significant at later time points, 
and had no effect on apoptosis. When the influence 
of DDM was assessed on cell migration, an inverse 
dose effect was observed. 0.1 µg/mL DDM stimulated 
migration of cells through the collagen matrix, whilst 
no influence in cell migration was observed in the 
presence 10 µg/mL DDM.
Influence of fractionating growth factors from 
DDM using heparin affinity chromatography
Growth factors were fractionated from DDM by 
virtue of their affinity to heparin (Fig. 4). 280 nm 
absorbance elution profiles indicated that the 
majority of the DDM constituents failed to bind to the 
column, passing into the flow through (FT) eluent. 
Consistent with the low concentration of growth 
Fig. 3. (A) DDM reduced the expansion of FM-BBMSCs, which appeared to be dose dependent, with 
significant reduction for cells supplemented with 10 μg/mL compared to non-supplemented cells observed 
at all time points and significance obtained for cells with 1 μg/mL DDM after 48 h. (B) 10 μg/mL DDM was 
the only concentration observed to significantly inhibited cell apoptosis as demonstrated by a reduction 
in the fluorescence read-out. (C) 10 μg/mL DDM also inhibited the migration of cells through a collagen 
matrix, whilst 0.1 μg/mL DDM promoted cell migration, compared to the non-supplemented control. 
(D) 10 μg/mL DDM supplementation was sufficient to induce deposition of mineralised nodules by the 
FM-BMMSCs as visualised by Alizarin Red staining and (E) the significant increase in gene expression 
for RunX2, Col1A1 and OC as determined by qPCR. Osteogenic induction media represented a positive 
control. n = 3 for all assays identifying cellular behaviour. *= p < 0.05, ** = p < 0.01, *** = p < 0.001. White 
scale bars represent 100 μm.
A B C
D E
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factors quantified in DDM, a small eluting peak was 
observed in fraction EL1 and minimal protein was 
detected in EL2 (Fig. 4B). ELISAs were performed, 
as a within assay triplicate, on one occasion (due to 
limitation of material) but indicated that over half 
of the BMP-2 and approximately 21.6 % of TGF-β1 
was present in the FT fraction (Fig. 3C). Western blot 
analysis of the FT demonstrated both biglycan and 
decorin as present (Fig. 4D). Insufficient material 
prevented similar analysis of biglycan and decorin 
in EL1 and EL2. Approximately 36 % of total TGF-β1 
present in DDM bound heparin, eluting in EL2, whilst 
approximately 7 % of BMP-2 was present in EL1 and 
EL2 combined (Fig. 4C).
Whilst total fractionation of growth factors was 
not achieved, fractionation influenced activity 
on FM-BMMSCs (Fig. 5; n = 3 for all analysis on 
cell behaviour). Compared to supplementation 
with whole DDM, constituents in eluted fractions 
appeared to increase cell expansion to levels 
approaching rates observed for non-supplemented 
cells, although a statistically significant difference was 
achieved when comparing whole DDM with EL1 (Fig. 
5A). EL1 and EL2 demonstrated similar expansion 
rates to those observed for non-supplemented cells 
(Fig. 5A). Compared with whole DDM, fractionated 
samples also had a reduced osteogenic potential as 
demonstrated by a lack of stimulation of RunX2 gene 
Fig. 4. Fractionation of growth factors using heparin affinity chromatography. (A) DDM was applied to heparin 
column and based on protein elution profiles, measuring 280 nm absorbance, eluting fractions were pooled to 
produced non-binding flow through (FT) fraction and fractions with increasing binding potential of EL1 and 
EL2. (B) Protein concentration was measured for each fraction and expressed as a percentage of the whole 
DDM, indicating low level binding of growth factors to the column, consistent with the low concentration 
levels of growth factors present in DDM. (C) Growth factors in each fraction were estimated using ELISA 
(performed in triplicate on two separate occasions; n = 2 due to insufficient material) and (D) the presence 
of biglycan and decorin confirmed by Western blot analysis using the appropriate primary antibodies.
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expression (Fig. 5B) and no or weak mineralised 
nodule formation, visualised by Alizarin red (Fig. 
5C).
Immuno-precipitation of biglycan and decorin 
from DDM
Western blot analysis confirmed the single depletion 
of biglycan or decorin from the DDM (−BGN and 
−DCN respectively). Dual depletion of both decorin 
and biglycan from DDM was also achieved (−BGN/
DCN). Analysis of the immuno-precipitated products 
(+BGN, +DCN and +BGN/DCN) confirmed the co-
precipitation of TGF-β1, which was not detected 
in the immuno-depleted DDM counterparts (Fig. 
6A). Immuno-depleted −BGN or −DCN abolished 
the inhibitory effect whole DDM produced on cell 
expansion (observed when DDM is compared with 
non-supplemented control (Fig. 6B)). Immuno-
precipitated +BGN and +DCN increased cell 
expansion compared to the non-supplemented 
control. Immuno-depletion for −BGN/DCN produced 
results similar to DDM, whilst the immuno-
precipitated product +BGN/DCN produced cell 
expansion rates similar to the non-supplemented 
control. This study also considered the effect of 
immuno-precipitation on osteogenic potential as 
judged by gene expression for RunX2 (Fig. 6C) and 
deposition of mineralising nodules staining with 
Alizarin Red (Fig. 6D). Immuno-depleted −BGN and 
dual depletion for −BGN/DCN abolish osteogenic 
potential; immuno-precipitated +BGN or +BGN/
DCN produced an osteogenic effect, albeit less than 
that observed for whole DDM; immuno-depleted 
−DCN slightly reduced osteogenic potential, and 
+DCN failed to induce either RunX2 expression or 
deposition of mineralising nodules.
Discussion
In vivo, dentine matrix components have been 
observed to promote mineralised dentine tissue 
repair within the tooth (Reis-Filho et al., 2012; Chun 
et al., 2011) and in promoting bone repair (de Oliveira 
et al., 2013; Gomes et al., 2008). DDM can thus be 
described to represent a physiologically optimised 
model matrix for promoting osteogenic signalling. A 
major aim of this study was to quantify in DDM the 
physiological concentrations of potential candidate 
growth factors recognised to act synergistically to 
elicit osteogenic potency (Kanczler et al., 2010; Tachi 
et al., 2011; Simmons et al., 2004). Notably TGF-β1 
DDM was found to be the most abundant growth 
factor (15.6 ng/mg), with levels more than double 
those identified for BMP-2, FGF, PDGF and VEGF. 
The molecular weight of TGF-β1 (52 kDa) suggests 
Fig. 5. The influence of fractions following heparin affinity chromatography on FM-BMMSCs. (A) All 
fractions appeared abolish the observed influence of whole DDM in decreasing cell expansion when 
compared to non-supplemented control cells, with statistical significance achieved of a higher cell expansion 
observed for cells supplement with EL1 compared with whole DDM. (B) Whole DDM increased the gene 
expression of RunX2 in FM-BMMSCs. For all fractions no increase in RunX2 was observed. (C) Following 
continued culture in the presence of the fractionated samples to 28 d, small nodules with faint staining 
for Alizarin Red were observed for FT fraction, whilst no mineralising nodule formation was observed for 
EL1 and EL2. Supplementation with whole DDM demonstrated reproducible results compared to Fig. 2. 
All cell based assays were performed in triplicate on three separate occasions. *= p < 0.05, ** = p < 0.01, *** 
= p < 0.001. White scale bars represent 100 μm.
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it is present as the unprocessed precursors (Gentry 
et al., 1988), although this form is predicted to be 
biologically active (Baillie et al., 1996). TGF-β1 can 
induce new bone formation when injected into 
critical size defects (Blom et al., 2001), where it acts 
co-operatively with BMPs to induce osteogenic 
differentiation (Lee et al., 2003; Lee et al., 2000). This 
is consistent with the observation that both growth 
factors can activate independently RunX2, although 
only BMP-2 activates the osteogenic pathway by Dlx-
5 expression (Lee et al., 2003). TGF-β can also induce 
BMP synthesis in the osteoprogenitor cells (Bostrom, 
1998). TGF-β1 also signals synergistically with 
growth factors such as FGFs (Mansukhani et al., 2000) 
and IGFs (Hughes et al., 2006), where collectively they 
have been attributed prominent roles in the migration 
of MSC and macrophages to the wound healing 
site, to induce MSC proliferation and stimulate the 
production of a collagenous osteoid matrix. Other 
synergistic signalling networks are also observed in 
DDM. VEGF is recognised as an important mitogen 
regulating budding of new endothelial cells for re-
vascularisation (Dimitriou et al., 2005). Its action has 
been shown to be enhanced by PDGF and basic FGF 
(Al-Aql et al., 2008), which are also identified in DDM 
in the present study.
 Within our study, 10 µg/mL of DDM was the 
minimal concentration capable of inducing an 
osteogenic response, which correlated with a 
decreased cell proliferation. At this concentration, 
DDM significantly reduced apoptotic cell numbers, 
indicating a role for promoting cell survival. 
However, at low concentrations of 0.1 µg/mL, 
DDM presented a chemo-attractant role, inducing 
migration of cells through a collagen matrix, whilst 
10 µg/mL inhibited cell migration. Similar actions 
for DDM preparations have been noted for dental 
pulp stem cells (Lee et al., 2015; Gonçalves et al., 
2016; Liu et al., 2016) although it should be noted that 
for these studies the demineralised dentine extract 
was prepared using different protocols that varied 
around the theme of demineralising the mineralised 
tissue and thus would lead to DDM of different 
composition to that identified in the present study. 
As a direct comparison, for DDM prepared following 
the same protocol (Lee et al., 2015), the up-regulation 
of bone forming markers in dental pulp stem cells 
has been shown to be induced with DDM at 1 µg/
mL, with 10 µg/mL DDM significantly increasing cell 
proliferation, thus highlighting differential effects of 
DDM on cells from different tissue sources. Within 
the culture media in our study, 10 µg/mL equates to 
approximately 110 pg/mL of TGF-β1 and 50 pg/mL 
of BMP-2, FGF and PDGF. One hundred-fold lower 
concentrations induce MSC migration. These levels 
are multiple times lower than the plethora of in vitro 
studies investigating one or two growth factors. The 
results emphasise a strong therapeutic potential for 
these physiological levels of growth factors when 
considering placement of DDM in the following bone 
healing site scenario in vivo. DDM first promotes 
the migration of BMMSCs along a chemo-attractant 
gradient of increasing concentration of stimulatory 
factors. Migratory potential is subsequently negated 
when the cell reaches the wound healing site where 
the higher concentration of DDM enhances BMMSC 
survival, expansion and subsequent osteogenic 
differentiation. The present study also indicated 
how the ratio of growth factors, operating via 
various additive or opposing regulatory signalling 
pathways, are important in producing an overall 
osteogenic effect. When DDM was fractionated, 
although heparin binding fractions contained TGF-β1 
and BMP-2 (EL1 and EL2), supplementation of FN-
BMMSCs with these fractions failed to induce an 
osteogenic effect. Unbound DDM (FT), also contained 
reduced levels of TGF-β1 and BMP-2 (21.6 % and 58 % 
of total present in whole DDM), and also produce less 
intensely stained mineralising nodules.
 This study additionally investigated the bioactive 
contribution of decorin and biglycan to the DDM, as 
matrix components able to bind TGF-β1 and BMP-2 
(Baker et al., 2009). Indeed, immuno-precipitation 
of either biglycan or decorin from the DDM was 
accompanied by the co-precipitation of TGF-β1. Our 
results are notable for indicating a strong osteogenic 
inductive role for biglycan, but not for decorin. 
DDM depletion for biglycan abolished osteogenic 
differentiation, but precipitated biglycan supported 
an osteogenic response by the FN-BMMSC cells. 
Decorin-depleted DDM produced an osteogenic 
response, but precipitated decorin did not. These 
observations mirror knock-out studies assessing roles 
for biglycan and decorin. In vivo, biglycan-/- mice 
experience reduced bone growth and skeletal mass 
compared to wild-type animals (Xu et al., 1998), in 
addition to reduced callus size and less woven bone 
at the fracture site (Berendsen et al., 2014). Decorin-
depletion in vivo did not affect bone quality, although 
double depletion of both decorin and biglycan 
produced mice with severe bone defects (Young et 
al., 2006). In vitro, transfection of MC3T3-E1 cells 
with biglycan enhances matrix mineralisation, whilst 
mineralisation is depressed in biglycan-KO cells 
(Parisuthiman et al., 2005). These studies have led 
to the proposal that biglycan possesses modulatory 
effects on growth factor activities by sequestering 
TGF-β1 and preventing over-activation of signalling 
(Bi et al., 2005), and enhancing BMP-4 (Chen et al., 
2004) and BMP-2 signalling pathways (Berendsen et 
al., 2011). Furthermore, biglycan has been reported to 
increase RunX2 transcription as a pericellular ligand 
binding participant in Wnt signalling (Nikitovic et al., 
2012; Nastase et al., 2012).
 Within this study, precipitated biglycan or decorin 
also enhanced cell expansion greater than the non-
supplemented control, which may also be attributable 
to co-precipitating TGF-β1. This result further 
supports proposed roles for biglycan synthesis in 
directing proliferation and initiation of osteoblast 
differentiation in bone derived MSCs/precursor 
cells (Waddington et al., 2003b; Roberts et al., 2008). 
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SJ Avery et al.                                                                                                         Dentine matrix enhances bone repair
However, the cellular influence of biglycan is likely 
to be dependent on growth factor concentration and 
cross-talk from other signalling pathways, and this is 
demonstrated in the present study. Cell expansion in 
the presence of both precipitated biglycan / decorin 
combined, where TGF-β1 concentration would be 
higher, was similar to non-supplemented control 
levels. Supplementation with whole DDM, (higher 
levels of TGF-β1, again), reduces cell expansion 
compared with the control. Collectively, these results 
highlight the complex signalling milieu of bone 
healing. While indicating osteogenic roles for growth 
factors, which necessitates TGF-β1 co-operative 
action with BMP-2 and other growth factors, there is 
also a necessary requirement for other matrix proteins 
such as biglycan to enhance bioactivity.
Conclusion
This study has identified bioactive utility for DDM 
in facilitating cell migration, promoting cell survival, 
regulating proliferation and promoting osteoblast 
differentiation for enhanced bone repair. Analyses 
identified optimal growth factor combinations, with 
prominent roles for TGB-β1, along with biglycan in 
enhancing an osteogenic response. DDM presents an 
attractive base for development of a graft material 
for augmenting bone repair, but significantly one 
where growth factors are present at pg levels, 
negating the toxicity issues and potential for ectopic 
mineralisation encountered in the clinical use of 
single recombinant forms of growth factors, such as 
BMP-2. Furthermore, DDM has the capacity to restore 
compromised signalling environments where in vivo 
studies have already demonstrated the potential of 
DDM to ameliorate delayed diabetic bone healing 
(Gomes et al., 2008). Levels and ratios of growth 
factor components are critical to its bioactivity, 
since fractionation or depletion of components in 
DDM abrogated osteogenic potential, emphasising 
that it is the whole DDM matrix that is prerequisite 
to present an optimised signalling environment 
to the wound healing site. Of note, DDM contains 
matrix proteins such as dentine sialoprotein, dentine 
phosphoprotein, bone sialoprotein, osteopontin, 
dentine matrix protein-1 and matrix extracellular 
phosphoglycoprotein (MEPE), with associated 
proposed signalling roles in the early reparative 
events (Smith et al., 2012); although their roles for a 
more comprehensive evaluation of DDM’s bioactivity 
have yet to be verified.
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